Furthermore, TCGA includes the Prosigna Prognostic Gene Signature Assay (formerly called the PAM50 test) to categorize breast tumors into five subtypes [luminal A (LumA), luminal B (LumB), Her2, Basal, and Normal-like] based on the expression level of genes, which have been found to be associated with breast cancer prognosis. The gene discussed is ERBB2; the disease is breast carcinoma.